ImmunoPrecise Antibodies Warned by Nasdaq

Victoria, British Columbia – ImmunoPrecise Antibodies Ltd. (IPA), an AI-driven biotherapeutics company, has received a notification from the Nasdaq Global Market indicating non-compliance with its minimum bid price requirement. The notification, dated August 19, 2024, highlights that IPA's common shares have closed below the US$1.00 threshold for 30 consecutive business days, from July 5 to August 15, 2024. IPA is recognized for its innovative approach in biotherapeutic research, utilizing systems biology, multi-omics modeling, and advanced artificial intelligence to enhance its proprietary technologies. The company offers a comprehensive range of services, including therapeutic biologics discovery and development, aimed at assisting partners in creating novel biologics to tackle complex medical challenges. Despite the current setback, IPA maintains that its forward-looking statements are grounded in reasonable expectations based on known facts. However, the company acknowledges that actual results may differ significantly due to various uncontrollable factors, including market conditions and broader economic influences in the U.S., Canada, and globally. The company advises stakeholders to review its quarterly and annual filings with Canadian and U.S. securities commissions for further insights into potential risks and uncertainties. IPA emphasizes that its forward-looking statements are valid only as of the press release date and does not commit to updating them in light of new information.